209 related articles for article (PubMed ID: 34508604)
1. Meta-Analysis of Quality of Life in Cancer Patients Treated With Immune Checkpoint Inhibitors.
Gonzalez BD; Eisel SL; Bowles KE; Hoogland AI; James BW; Small BJ; Sharpe S; Hyland KA; Bulls HW; Christy SM; Mansfield J; Nelson AM; Alla R; Maharaj K; Kennedy B; Lafranchise E; Williams NL; Jennewein S; Oswald LB; Postow MA; Dicker AP; Jim HSL
J Natl Cancer Inst; 2022 Jun; 114(6):808-818. PubMed ID: 34508604
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
Boutros A; Bruzzone M; Tanda ET; Croce E; Arecco L; Cecchi F; Pronzato P; Ceppi M; Lambertini M; Spagnolo F
Eur J Cancer; 2021 Dec; 159():154-166. PubMed ID: 34753012
[TBL] [Abstract][Full Text] [Related]
3. Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care-A Systematic Review.
Hall ET; Singhal S; Dickerson J; Gabster B; Wong HN; Aslakson RA; Schapira L;
J Pain Symptom Manage; 2019 Jul; 58(1):137-156.e1. PubMed ID: 30905677
[TBL] [Abstract][Full Text] [Related]
4. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
[TBL] [Abstract][Full Text] [Related]
5. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
6. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
Front Immunol; 2021; 12():760737. PubMed ID: 34925331
[TBL] [Abstract][Full Text] [Related]
7. Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials: A Systematic Review and Meta-analysis.
Pala L; Sala I; Oriecuia C; De Pas T; Queirolo P; Specchia C; Cocorocchio E; Ferrucci P; Patanè D; Saponara M; Pennacchioli E; Coppola S; Viale G; Giaccone G; Gelber RD; Bagnardi V; Conforti F
JAMA Netw Open; 2022 Aug; 5(8):e2226252. PubMed ID: 35972744
[TBL] [Abstract][Full Text] [Related]
8. Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors.
Petrillo LA; El-Jawahri A; Nipp RD; Lichtenstein MRL; Durbin SM; Reynolds KL; Greer JA; Temel JS; Gainor JF
Cancer; 2020 May; 126(10):2288-2295. PubMed ID: 32142165
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials.
Liu H; Luo SX; Jie J; Peng L; Wang S; Song L
Front Immunol; 2023; 14():1115305. PubMed ID: 36926326
[TBL] [Abstract][Full Text] [Related]
10. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
11. Association of proton pump inhibitor use with survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Chen B; Yang C; Dragomir MP; Chi D; Chen W; Horst D; Calin GA; Li Q
Ther Adv Med Oncol; 2022; 14():17588359221111703. PubMed ID: 35860836
[TBL] [Abstract][Full Text] [Related]
12. Impact of corticosteroid use on outcomes of non-small-cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Zhang H; Li X; Huang X; Li J; Ma H; Zeng R
J Clin Pharm Ther; 2021 Aug; 46(4):927-935. PubMed ID: 34138497
[TBL] [Abstract][Full Text] [Related]
13. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
14. Type 1 diabetes with immune checkpoint inhibitors: A systematic analysis of clinical trials and a pharmacovigilance study of postmarketing data.
Zhu J; Luo M; Liang D; Gao S; Zheng Y; He Z; Zhao W; Yu X; Qiu K; Wu J
Int Immunopharmacol; 2022 Sep; 110():109053. PubMed ID: 35978507
[TBL] [Abstract][Full Text] [Related]
15. Impact of the gut microbiome on immune checkpoint inhibitor efficacy-a systematic review.
Pierrard J; Seront E
Curr Oncol; 2019 Dec; 26(6):395-403. PubMed ID: 31896938
[TBL] [Abstract][Full Text] [Related]
16. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Mori K; Abufaraj M; Mostafaei H; Quhal F; Fajkovic H; Remzi M; Karakiewicz PI; Egawa S; Schmidinger M; Shariat SF; Gust KM
Eur Urol; 2021 Jun; 79(6):783-792. PubMed ID: 33172722
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
18. Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events: A Systematic Review and Meta-analysis.
Farooq MZ; Aqeel SB; Lingamaneni P; Pichardo RC; Jawed A; Khalid S; Banskota SU; Fu P; Mangla A
JAMA Netw Open; 2022 Apr; 5(4):e227722. PubMed ID: 35438755
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies.
Xie W; Huang H; Xiao S; Fan Y; Deng X; Zhang Z
Autoimmun Rev; 2020 Dec; 19(12):102687. PubMed ID: 33131688
[TBL] [Abstract][Full Text] [Related]
20. Antibiotic administration shortly before or after immunotherapy initiation is correlated with poor prognosis in solid cancer patients: An up-to-date systematic review and meta-analysis.
Yang M; Wang Y; Yuan M; Tao M; Kong C; Li H; Tong J; Zhu H; Yan X
Int Immunopharmacol; 2020 Nov; 88():106876. PubMed ID: 32799113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
